Øget risiko for venøs og arteriel hjerte-kar-lidelse ved inflammatorisk tarmsygdom

Ugeskrift for Laeger

Volumn 174, Issue 48, 2012, Pages 3003-3006

  Kristensen, Søren Lund ^a   Ahlehoff, Ole ^a,b   Lindhardsen, Jesper ^a   Gislason, Gunnar ^a   Nielsen, Ole Haagen ^a   Hansen, Peter Riis ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b ROSKILDE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CROHN DISEASE; ENTERITIS; HUMAN; LUNG EMBOLISM; PATHOLOGY; RISK FACTOR; SMALL INTESTINE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINE, SMALL; PULMONARY EMBOLISM; RISK FACTORS; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84872513144     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
2. Prandoni P, Bilora F, Marchiori A et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003;348:1435-41.
3. Sorensen HT, Horvath-Puho E, Pedersen L et al. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007;370:1773-9.
4. Kaptoge S, Di Angelantonio E, Lowe G et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40.
5. Glynn RJ, Danielson E, Fonseca FA et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009;360: 1851-61.
6. Bargen JABN. Extensive arterial end venous thrombosis complicating chronic ulcerative colitis. Arch Intern Med 1936;58:17-31.
7. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375:657-63.
8. Zitomersky NL, Verhave M, Trenor CC, 3rd. Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention. Inflamm Bowel Dis 2011;17:458-70.
9. Osterman MT, Yang YX, Brensinger C et al. No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease. Clin Gastroenterol Hepatol 2011;9:875-80.
10. Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol 2008;6:41-5.
11. Kaplan MJ. Management of cardiovascular disease risk in chronic inflammatory disorders. Nat Rev Rheumatol 2009;5:208-17.
12. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011;140:1756-67.
13. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361: 2066-78.
14. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011;365:1713-25.
15. Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol 2005;3:617-28.
16. Zhao Q. Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J Leukoc Biol 2010;88:41-55.
17. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-40.
18. van Leuven SI, Hezemans R, Levels JH et al. Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease. J Lipid Res 2007;48:2640-6.
19. Gresele P, Momi S, Migliacci R. Endothelium, venous thromboembolism and ischaemic cardiovascular events. Thromb Haemost 2010;103:56-61.
20. Bernstein CN, Sargent M, Vos HL et al. Mutations in clotting factors and inflammatory bowel disease. Am J Gastroenterol 2007;102:338-43.
21. Kappelman MD, Horvath-Puho E, Sandler RS et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a populationbased nationwide study. Gut 2011;60:937-43.
22. Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:2272-80.
23. Novacek G, Weltermann A, Sobala A et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2010;139:779-87.
24. Solem CA, Loftus EV, Tremaine WJ et al. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004;99:97-101.
25. Andersohn F, Waring M, Garbe E. Risk of ischemic stroke in patients with Crohn's disease: a population-based nested case-control study. Inflamm Bowel Dis 2010;16:1387-92.
26. Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol 2007;102:662-7.
27. Yarur AJ, Deshpande AR, Pechman DM et al. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol 2011;106:741-7.
28. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol 2007;157:545-59.
29. Micha R, Imamura F, Wyler von Ballmoos M et al. Systematic review and metaanalysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011;108:1362-70.
30. Danese S, Sans M, Scaldaferri F et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol 2006;176:2617-24.